ECHS1
protein-codingenoyl-CoA hydratase, short chain 1, the group of MicroRNA protein coding host genes
Gene summary
The protein encoded by this gene functions in the second step of the mitochondrial fatty acid beta-oxidation pathway. It catalyzes the hydration of 2-trans-enoyl-coenzyme A (CoA) intermediates to L-3-hydroxyacyl-CoAs. The gene product is a member of the hydratase/isomerase superfamily. It localizes to the mitochondrial matrix. Transcript variants utilizing alternative transcription initiation sites have been described in the literature. [provided by RefSeq, Jul 2008]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~10.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0014563
Submitter: Genomics England PanelApp
Inheritance Pattern: AR
Disease ID:MONDO:0009723
Submitter: ClinGen
The relationship between ECHS1 and Leigh syndrome spectrum was evaluated using the ClinGen Clinical Validity Framework as of September 9, 2019. The ECHS1 gene encodes the mitochondrial short-chain enoyl-CoA hydratase (SCEH), which functions in the beta-oxidation of short chain fats, the isoleucine catabolic pathway, and the valine catabolic pathway. In the valine catabolic pathway, SCEH acts upstream of HIBCH and converts methacrylyl-CoA to (S)-3-hydroxyisobutyryl-CoA and acryloyl-CoA to 3-hydroxypropionyl-CoA. The exact disease mechanism has not been fully elucidated, but elevated levels of the SCEH substrate methacrylyl-CoA are toxic and impair functioning of the pyruvate dehydrogenase complex and the oxidative phosphorylation complexes (PMID: 25125611). The ECHS1 gene was first reported in relation to autosomal recessive Leigh syndrome spectrum in 2014 (PMID 25125611). Evidence supporting this gene-disease relationship includes case-level data and experimental data. This curation included 16 variants in 12 cases from 7 publications (PMIDs: 26000322, 25393721, 25125611, 28409271, 29575569, 28755360, 26099313). No segregation data were available. Loss of function is implicated as the mechanism of disease. This gene-disease association is also supported by biochemical function, expression, functional alterations in patient cells, and rescue experiments (PMIDs: 27977873, 25613900, 26251176, 25125611, 26000322). In summary, there is definitive evidence to support this gene-disease relationship, including that more than three years have elapsed from the first proposal of the association. This classification was approved by the NICHD U24 ClinGen Mitochondrial Disease Gene Curation Expert Panel on September 9, 2019 (SOP Version 7).
Inheritance Pattern: AR
Disease ID:MONDO:0014563
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0014563
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0014563
Submitter: ClinGen
Inheritance Pattern: AR
Disease ID:MONDO:0014563
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0014563
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0014563
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Biochemical; Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to ECHS1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_004092.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 5 | 80 | 1 | 87 | |
| missense | 10 | 45 | 99 | 5 | 159 | |
| nonsense | 2 | 2 | 1 | 5 | ||
| start loss | 3 | 2 | 5 | |||
| frameshift | 7 | 7 | 2 | 16 | ||
| splice donor/acceptor (+/-2bp) | 2 | 3 | 7 | 12 | ||
| Total | 24 | 60 | 114 | 85 | 1 | 284 |
Highest pathogenic variant AF is 0.00017585876
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_004083.3 | 8 | MANE Select | |
| Ensembl | ENSP00000357535.3 | 8 | MANE Select | |
| Ensembl | ENSP00000527623.1 | 9 | Standard | |
| Ensembl | ENSP00000527623.1 | 9 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Tryptophan metabolism - Homo sapiens (human)
- Butanoate metabolism - Homo sapiens (human)
- beta-Alanine metabolism - Homo sapiens (human)
- Lysine degradation - Homo sapiens (human)
- Propanoate metabolism - Homo sapiens (human)
Biological Process
- fatty acid beta-oxidation
Molecular Function
- enoyl-CoA hydratase activity
- protein binding
Cellular Component
- mitochondrion
- mitochondrial matrix
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000368547
- Coding exons
- 8
- Length
- 11210
- Individuals with no LoFs
- 125682
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 59
- Defined
- 125741
- p
- 0.000235
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.863 | 131 | 162 | 0.809 | 0.00000908 | 1867 |
| Missense (PolyPhen) | 41 | 74.02 | 0.55391 | 823 | ||
| Synonymous | -0.419 | 70 | 65.7 | 1.07 | 0.00000429 | 536 |
| Loss of Function | 1.69 | 7 | 13.8 | 0.509 | 6.78e-7 | 172 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00049 | 0.00049 | rare |
| Latino/Admixed American | 0.00023 | 0.00023 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00016 | 0.00016 | rare |
| Finnish | 0.00014 | 0.00014 | rare |
| European (Non-Finnish) | 0.00023 | 0.00023 | rare |
| South Asian | 0.00030 | 0.00029 | rare |
| Other | 0.00033 | 0.00033 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Straight-chain enoyl-CoA thioesters from C4 up to at least C16 are processed, although with decreasing catalytic rate. Has high substrate specificity for crotonyl-CoA and moderate specificity for acryloyl-CoA, 3-methylcrotonyl-CoA and methacrylyl-CoA. It is noteworthy that binds tiglyl-CoA, but hydrates only a small amount of this substrate. {ECO:0000269|PubMed:26251176}.;
Intolerance Scores
- LoFtool
- 0.498
- RVIS EVS
- -0.07
- RVIS percentile EVS
- 48.35
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.999
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |